Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Torrent Pharmaceuticals advances on acquiring BPI

19-Jan2018

Torrent Pharmaceuticals advances on acquiring BPI

Torrent Pharmaceuticals is currently trading at Rs. 1436.70, up by 12.45 points or 0.87% from its previous closing of Rs. 1424.25 on the BSE.

The scrip opened at Rs. 1440.00 and has touched a high and low of Rs. 1442.00 and Rs. 1429.00 respectively. So far 1,401 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1572.10 on 31-Mar-2017 and a 52 week low of Rs. 1143.50 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 1445.05 and Rs. 1372.00 respectively. The current market cap of the company is Rs. 24,231.56 crore.

The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.52% and 10.24% respectively.

Torrent Pharmaceuticals has acquired Bio-Pharm, Inc. (BPI), a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA. This acquisition is an important step for increasing Torrent's presence in the United States, is consistent with our strategy of dosage form diversification, and provides us with new capabilities including manufacturing and R&D presence in the USA. Torrent plans further investments to expand the BPI facilities including R&D capabilities and will increase the number of product filings from BPI.

Established in 1992, BPI has a proven track record in the research & development and manufacturing of oral solutions, suspensions and suppositories. Its 75,000 square feet USFDA registered facility has manufacturing capabilities for controlled substances which can be manufactured in US only as per Government guidelines.  To date, BPI has 10 approved ANDAs, 10 ANDAs under review at the FDA for itself and its partners and has an additional 17 products under development.

Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.



Related News

View all news

Reliance Industries slips despite reporting 10% rise in Q4 consolidated net profit

Reliance Industries is currently trading at Rs. 1356.35, down by 26.55 points or 1.92% from its previous closing of Rs. 1382.90 on the BSE.The scrip opened at Rs. 1364.00 and has touched a high and low......

Future Retail trades in green on the BSE

Future Retail is currently trading at Rs. 430.80, up by 0.75 points or 0.17% from its previous closing of Rs. 430.05 on the BSE.The scrip opened at Rs. 430.00 and has touched a high and low of Rs. 435.15......

GVK Power zooms with its arms inking pact with ADIA, NIIF

GVK Power & Infrastructure is currently trading at Rs. 7.98, up by 0.66 points or 9.02% from its previous closing of Rs. 7.32 on the BSE.The scrip opened at Rs. 7.74 and has touched a high and......

Top News

View all news

Bank of Baroda's board to consider issuance of equity shares of Rs 5,042 crore to Govt

Bank of Baroda's board is going to consider issuance of equity shares of Rs 5,042 crore to Government of India on a Preferential Basis. The meeting of the Board of Directors of the Bank is scheduled to......

Gujarat Petrosynthese to invest surplus funds in mutual funds, bonds, securities, shares

Gujarat Petrosynthese has received an approval to invest surplus funds in mutual funds, bonds, securities, shares, inter corporate deposits etc. to optimize its returns. The Board of Directors of the Company......

Reliance's Retail Unit delivers record-breaking performance in revenue, profits during FY19

Reliance Industries' Retail Unit--Reliance Retail has delivered a record-breaking performance in revenue and profits growth for the year 2018-19. Segment Revenue for FY19 grew by 88.7% Y-o-Y to Rs 130,566......